StockNews.com began coverage on shares of Vascular Biogenics (NASDAQ:VBLT – Get Rating) in a report issued on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, Zacks Investment Research lowered Vascular Biogenics from a buy rating to a hold rating in a report on Friday, January 7th. One analyst has […]
Vascular Biogenics (NASDAQ:VBLT – Get Rating) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.03), MarketWatch Earnings reports. Vascular Biogenics had a negative net margin of 3,612.61% and a negative return on equity of 66.02%. During the […]
StockNews.com began coverage on shares of Vascular Biogenics (NASDAQ:VBLT – Get Rating) in a research note published on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, Zacks Investment Research lowered Vascular Biogenics from a buy rating to a hold rating in a report on Friday, January 7th. Two investment […]
Vascular Biogenics (NASDAQ:VBLT – Get Rating) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, March 23rd. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. NASDAQ VBLT opened at $1.15 on Thursday. Vascular Biogenics has a 1-year low of $1.10 and a 1-year […]
Spectrum Planning & Advisory Services Inc. bought a new position in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT – Get Rating) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,000 shares of the biopharmaceutical company’s stock, valued at approximately $32,000. Several […]